EGFR and carcinoma: Predominant accumulations of morpholino-[124I]IPQA in EGFR-expressing L858R and E746-A750 del carcinoma tumor xenografts reflect the high level of phosphorylated EGFR expression and activity in those tumor cells, which are known to be responsive to therapy with small molecular inhibitors of EGFR (e.g., Gefitinib) [14].